Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 2(3)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01259856Phase 3Completed

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Role: lead

NCT01259817Phase 2Completed

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

Role: lead

NCT01298934Phase 1Unknown

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Role: lead

NCT00940784Phase 2Withdrawn

Clopidogrel and Aspirin for the Treatment of Polycythemia Vera

Role: lead

NCT00668421Phase 1Unknown

CEP-701 (Lestaurtinib) in Myelofibrosis

Role: lead

NCT00667277Phase 2Terminated

Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis

Role: lead

All 6 trials loaded